{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:46:59Z","timestamp":1785210419954,"version":"3.55.0"},"reference-count":7,"publisher":"Akademiai Kiado Zrt.","issue":"41","license":[{"start":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T00:00:00Z","timestamp":1697328000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2023,10,15]]},"abstract":"<jats:p>A myxoinflammatoricus fibroblastos sarcoma (MIFS) ritka, \u2019low-grade\u2019,\n                    f\u00e1jdalommentes, mesenchymalis eredet\u0171 daganat. A l\u00e1gyr\u00e9sz- \u00e9s csonttumoroknak az\n                    Eg\u00e9szs\u00e9g\u00fcgyi Vil\u00e1gszervezet (WHO) \u00e1ltal kiadott jelenlegi, 5. kiad\u00e1s\u00fa\n                    oszt\u00e1lyoz\u00e1s\u00e1ban a MIFS eset\u00e9ben nincs meghat\u00e1rozva pontos diagnosztikus\n                    genetikai elt\u00e9r\u00e9s. Egy 71 \u00e9ves n\u0151beteg eset\u00e9t mutatjuk be, akinek a\n                    k\u00f3rt\u00f6rt\u00e9net\u00e9ben benignus essentialis hypertensio szerepelt. A jobb s\u00edpcsontja\n                    f\u00f6l\u00f6tti elv\u00e1ltoz\u00e1s miatt ker\u00fclt kivizsg\u00e1l\u00e1sra. Az elv\u00e1ltoz\u00e1st 1,5 \u00e9vvel az\n                    orvosi megjelen\u00e9s el\u0151tt \u00e9szlelte, \u00e9s csak a b\u0151rfel\u00fcleten jelentkez\u0151 f\u00e1jdalom,\n                    er\u00f3zi\u00f3 \u00e9s papulak\u00e9pz\u0151d\u00e9s miatt kereste fel az eg\u00e9szs\u00e9g\u00fcgyi int\u00e9zm\u00e9nyt.\n                    Mikroszk\u00f3posan az elv\u00e1ltoz\u00e1s cellularis \u00e9s pleiomorph megjelen\u00e9s\u0171, nodularis\n                    szerkezet\u0171 volt, a subcutan zs\u00edrsz\u00f6vet \u00fan. l\u00e9pesm\u00e9zszer\u0171 infiltr\u00e1ci\u00f3j\u00e1val. A\n                    dermis kollag\u00e9nrostjai k\u00f6z\u00f6tt szint\u00e9n tumorsz\u00f6vet volt l\u00e1that\u00f3. A daganatsejtek\n                    nagyr\u00e9szt multinuclearis morfol\u00f3gi\u00e1t mutattak prominens, v\u00edrusos inclusioszer\u0171\n                    nucleolusszal, nagy mennyis\u00e9g\u0171 fibrillaris, gyakran vakuoliz\u00e1lt \u00e9s \u00fan.\n                    tej\u00fcvegszer\u0171 citoplazm\u00e1val. Az immunhisztok\u00e9miai vizsg\u00e1lat sor\u00e1n a tumorsejtek\n                    multifok\u00e1lis pozitivit\u00e1st mutattak CD34-, CD31-, podoplanin- (D2\u201340), ciklin-D1-\n                    \u00e9s epithelialis membr\u00e1nantig\u00e9n (EMA-) reakci\u00f3kkal. A tumorsejtek tov\u00e1bb\u00e1 diff\u00faz\n                    pozit\u00edvnak bizonyultak a simaizomaktinnal (SMA). Mivel az \u00e1ltalunk vizsg\u00e1lt\n                    elv\u00e1ltoz\u00e1s a jelenlegi WHO-oszt\u00e1lyoz\u00e1s minden l\u00e9nyeges krit\u00e9rium\u00e1nak megfelelt,\n                    az esetet \u2019high-grade\u2019 von\u00e1sokat mutat\u00f3 MIFS-nek k\u00f3rism\u00e9zt\u00fck. Tapasztalataink\n                    alapj\u00e1n a podoplanin, ciklin-D1, CD10, EMA, CD34 \u00e9s CD31 immunhisztok\u00e9miai\n                    reakci\u00f3kb\u00f3l \u00e1ll\u00f3 panel seg\u00edti a helyes diagn\u00f3zis fel\u00e1ll\u00edt\u00e1s\u00e1t. Eset\u00fcnk r\u00e1vil\u00e1g\u00edt\n                    e ritka, fok\u00e1lisan \u2019high-grade\u2019 von\u00e1sokat mutat\u00f3, a h\u00e9tk\u00f6znapokban kih\u00edv\u00e1st\n                    jelent\u0151 betegs\u00e9g sz\u00f6vettani jellemz\u0151ire. A diff\u00faz SMA-pozitivit\u00e1s ismert, de\n                    ritka jellemz\u0151je a daganatnak. Orv Hetil. 2023; 164(41): 1637\u20131641.<\/jats:p>","DOI":"10.1556\/650.2023.32891","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T08:34:00Z","timestamp":1697704440000},"page":"1637-1641","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":1,"title":["Az als\u00f3 v\u00e9gtag myxoinflammatoricus fibroblastos sarcom\u00e1ja"],"prefix":"10.1556","volume":"164","author":[{"given":"Mohammed","family":"Almakrami","sequence":"first","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, Pathologiai Int\u00e9zet Szeged, \u00c1llom\u00e1s u. 2., 6725 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Pancsa","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, Pathologiai Int\u00e9zet Szeged, \u00c1llom\u00e1s u. 2., 6725 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levente","family":"Kuthi","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, Pathologiai Int\u00e9zet Szeged, \u00c1llom\u00e1s u. 2., 6725 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Sejben","sequence":"additional","affiliation":[{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, Pathologiai Int\u00e9zet Szeged, \u00c1llom\u00e1s u. 2., 6725 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"ref0","unstructured":"1. Montgomery EA, Devaney KO, Giordano TJ, et al. Inflammatory myxohyaline tumor of distal extremities with virocyte or Reed-Sternberg-like cells: a distinctive lesion with features simulating inflammatory conditions, Hodgkin's disease, and various sarcomas. Mod Pathol. 1998; 11: 384-391."},{"key":"ref1","doi-asserted-by":"publisher","first-page":"254","DOI":"10.2350\/11-09-1090-CR.1","article-title":"Myxoinflammatory fibroblastic sarcoma: report of a case and review of the literature","volume":"15","author":"Alaggio","year":"2012","unstructured":"2. Alaggio R, Coffin CM, Dall'igna P, et al. Myxoinflammatory fibroblastic sarcoma: report of a case and review of the literature. Pediatr Dev Pathol. 2012; 15: 254-258.","journal-title":"Pediatr Dev Pathol"},{"key":"ref2","unstructured":"3. WHO Classification of tumours. Soft tissue and bone tumours, Volume 3. 5th edition. International Agency for Research on Cancer, Lyon, 2020."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1038\/s41379-020-0580-6","article-title":"Myxoinflammatory fibroblastic sarcoma: an immunohistochemical and molecular genetic study of 73 cases","volume":"33","author":"Suster","year":"2020","unstructured":"4. Suster D, Michal M, Huang H, et al. Myxoinflammatory fibroblastic sarcoma: an immunohistochemical and molecular genetic study of 73 cases. Mod Pathol. 2020; 33: 2520-2533.","journal-title":"Mod Pathol"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Ling MJ, Zonta M. Myxoinflammatory fibroblastic sarcoma. ANZ J Surg. 2022; 93: 367-368.","DOI":"10.1111\/ans.17774"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.5858\/arpa.2013-0549-RS","article-title":"Myxoinflammatory fibroblastic sarcoma: morphologic and genetic updates","volume":"138","author":"Ieremia","year":"2014","unstructured":"6. Ieremia E, Thway K. Myxoinflammatory fibroblastic sarcoma: morphologic and genetic updates. Arch Pathol Lab Med. 2014; 138: 1406-1411.","journal-title":"Arch Pathol Lab Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/RCT.0000000000000490","article-title":"Myxoinflammatory fibroblastic sarcoma: clinical, imaging, management and outcome in 29 patients","volume":"41","author":"Kumar","year":"2017","unstructured":"7. Kumar R, Lefkowitz RA, Neto AD. Myxoinflammatory fibroblastic sarcoma: clinical, imaging, management and outcome in 29 patients. J Comput Assist Tomogr. 2017; 41: 104-115.","journal-title":"J Comput Assist Tomogr"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/41\/article-p1637.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/164\/41\/article-p1637.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/164\/41\/article-p1637.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T12:12:17Z","timestamp":1697717537000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/41\/article-p1637.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,15]]},"references-count":7,"journal-issue":{"issue":"41"},"URL":"https:\/\/doi.org\/10.1556\/650.2023.32891","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,15]]}}}